Loading organizations...
Fontus Capital is a private equity and venture capital firm based in Shanghai and Beijing, China, that focuses on early-stage venture opportunities. The organization operates primarily within the broader Asian market, allocating institutional capital to emerging businesses across various undisclosed industry sectors. As a privately held investment vehicle, the firm maintains a highly confidential portfolio and does not publicly disclose specific financial metrics such as total assets under management, active fund sizes, or aggregate funding raised. Consequently, detailed information regarding its institutional limited partners, frequent lead co-investors, and specific portfolio companies remains proprietary and is not widely circulated across standard public market databases. The firm continues to execute its venture-stage investment strategy through its established dual-office presence in mainland China, although its exact founding year and the identities of its original managing partners are not currently documented.
Fontus Capital has 3 tracked investments across 3 companies. The latest tracked deal is $35.0M Pre-Series B in Lupeng Pharmaceutical in November 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 16, 2022 | Lupeng Pharmaceutical | $35.0M Pre-Series B | Temasek | Kaitai Capital, BIN LI, Lilly Asia Ventures, TF Capital |
| Nov 20, 2021 | Tavotek Biotherapeutics | $35.0M Series B | CS Capital | — |
| Dec 17, 2019 | Cellestia | $20.4M Series B | Fontus Capital, Partners Investment, PPF Group | — |